drugset / Trial / NCT02160106
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The phase I dose escalation study will investigate the safety, tolerability, and pharmacokinetics of the TGF-β pathway inhibitor TEW 7197 in subjects with advanced, refractory solid tumors.
Timeline
- Start
- 2014-07-29
- Primary completion
- 2018-07-31
- Completion
- 2018-08-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vactosertib | Small molecule | 30 mg | Oral |
| Subject | Vactosertib | Small molecule | 60 mg | Oral |
Indications
No indication recorded.